Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
Launched by LMC DIABETES & ENDOCRINOLOGY LTD. · Jul 27, 2017
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
Non-alcoholic fatty liver disease (NAFLD) is very commonly associated with type 2 diabetes mellitus (T2DM) 1. Alanine aminotransferase (ALT) is a common biomarker used to predict levels of NAFLD. The only class of antidiabetic agents thought to be protective of NAFLD are thiazolidinedione's. Few studies have investigated the effect of other antidiabetic agents on bio markers of fatty liver disease 2. A recent pooled analysis of randomized controlled trials that compared canagliflozin to either placebo or sitagliptin showed significant reductions in ALT in the canagliflozin cohorts, which we...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of T2DM based upon historical clinical diagnosis
- • Patients who initiated canagliflozin, dapagliflozin, liraglutide or sitagliptin by an LMC physician between January 2011 and December 2015, or patients who did not initiate a new diabetes therapy between June 2014 and June 2015.
- Exclusion Criteria:
- • Diagnosis of type 1 diabetes
- • Patients who switched to one of the study treatments from another medication of the same medication class
About Lmc Diabetes & Endocrinology Ltd.
LMC Diabetes & Endocrinology Ltd. is a leading clinical trial sponsor specializing in diabetes and endocrine disorders. With a commitment to advancing medical research and improving patient outcomes, LMC conducts innovative studies that evaluate new therapies and treatments in the field. The organization is dedicated to maintaining high ethical standards and compliance with regulatory requirements, ensuring the integrity of its clinical trials. By collaborating with healthcare professionals and leveraging state-of-the-art facilities, LMC aims to enhance the understanding of diabetes and related conditions, ultimately contributing to the development of effective solutions for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brampton, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials